Thomas Sisson

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. pmc Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis
    Thomas H Sisson
    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical Center, 1150 West Medical Center Drive, 6301 MSRB III, Ann Arbor, MI 48109 5642, USA
    Am J Respir Crit Care Med 181:254-63. 2010
  2. ncbi request reprint Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice
    Thomas H Sisson
    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
    Am J Physiol Lung Cell Mol Physiol 283:L1023-32. 2002
  3. pmc Expression of the reverse tetracycline-transactivator gene causes emphysema-like changes in mice
    Thomas H Sisson
    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical Center, 1150 West Medical Center Drive, 6301 MSRB III, Ann Arbor, MI 48109 0642, USA
    Am J Respir Cell Mol Biol 34:552-60. 2006
  4. pmc The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice
    Kristy A Bauman
    Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA
    J Clin Invest 120:1950-60. 2010
  5. pmc Plasminogen-mediated activation and release of hepatocyte growth factor from extracellular matrix
    Hiroto Matsuoka
    Pulmonary Critical Care Medicine Division, Department of Internal Medicine, University of Michigan Health Sciences Center, Ann Arbor, MI 48109, USA
    Am J Respir Cell Mol Biol 35:705-13. 2006
  6. ncbi request reprint Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin
    Michael H Lazar
    Department of Internal Medicine, University of Michigan Medical Center, 1150 West Medical Center Drive, 6301 MSRB III, Ann Arbor, MI 48109 0642, USA
    Am J Respir Cell Mol Biol 31:672-8. 2004
  7. doi request reprint Continuous oxygen use in nonhypoxemic emphysema patients identifies a high-risk subset of patients: retrospective analysis of the National Emphysema Treatment Trial
    Michael B Drummond
    Division of Pulmonary and Critical Care Medicine, The Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA
    Chest 134:497-506. 2008
  8. pmc Urokinase-type plasminogen activator increases hepatocyte growth factor activity required for skeletal muscle regeneration
    Thomas H Sisson
    Department of Medicine, University of Michigan, Ann Arbor, USA
    Blood 114:5052-61. 2009
  9. pmc Integrating health status and survival data: the palliative effect of lung volume reduction surgery
    Roberto Benzo
    Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota 55902, USA
    Am J Respir Crit Care Med 180:239-46. 2009
  10. pmc Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1
    Sheila Chuang-Tsai
    Department of Internal Medicine, Pulmonary and Critical Care Medicine Division, University of Michigan Health Sciences Center, Ann Arbor, Michigan 48109, USA
    Am J Pathol 163:445-52. 2003

Detail Information

Publications23

  1. pmc Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis
    Thomas H Sisson
    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical Center, 1150 West Medical Center Drive, 6301 MSRB III, Ann Arbor, MI 48109 5642, USA
    Am J Respir Crit Care Med 181:254-63. 2010
    ..Although these findings are compelling, there are no studies that demonstrate a direct role for the alveolar epithelium or, more specifically, type II cells in the scarring process...
  2. ncbi request reprint Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice
    Thomas H Sisson
    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
    Am J Physiol Lung Cell Mol Physiol 283:L1023-32. 2002
    ..By allowing the manipulation of plasminogen activation at different phases of the fibrotic process, this model will serve as a powerful tool in further investigations into the pathogenesis of pulmonary fibrosis...
  3. pmc Expression of the reverse tetracycline-transactivator gene causes emphysema-like changes in mice
    Thomas H Sisson
    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical Center, 1150 West Medical Center Drive, 6301 MSRB III, Ann Arbor, MI 48109 0642, USA
    Am J Respir Cell Mol Biol 34:552-60. 2006
    ..Therefore, when using this system to study emphysema pathogenesis, the inclusion of proper controls is essential for accurate data interpretation...
  4. pmc The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice
    Kristy A Bauman
    Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA
    J Clin Invest 120:1950-60. 2010
    ..These studies demonstrate crosstalk between plasminogen activation and PGE2 generation in the lung and provide a mechanism for the well-known antifibrotic actions of the fibrinolytic pathway...
  5. pmc Plasminogen-mediated activation and release of hepatocyte growth factor from extracellular matrix
    Hiroto Matsuoka
    Pulmonary Critical Care Medicine Division, Department of Internal Medicine, University of Michigan Health Sciences Center, Ann Arbor, MI 48109, USA
    Am J Respir Cell Mol Biol 35:705-13. 2006
    ..In conjunction with the previous in vivo study, these results suggest that plasminogen activation can protect the lung against fibrosis by increasing the availability of active HGF...
  6. ncbi request reprint Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin
    Michael H Lazar
    Department of Internal Medicine, University of Michigan Medical Center, 1150 West Medical Center Drive, 6301 MSRB III, Ann Arbor, MI 48109 0642, USA
    Am J Respir Cell Mol Biol 31:672-8. 2004
    ..The significant effect of uPA and PAI-1 on epithelial repair suggests a mechanism by which the plasminogen system may modulate pulmonary fibrosis...
  7. doi request reprint Continuous oxygen use in nonhypoxemic emphysema patients identifies a high-risk subset of patients: retrospective analysis of the National Emphysema Treatment Trial
    Michael B Drummond
    Division of Pulmonary and Critical Care Medicine, The Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA
    Chest 134:497-506. 2008
    ..Little is known regarding the clinical characteristics and survival of nonhypoxemic emphysema patients using continuous oxygen. Analysis of data from the National Emphysema Treatment Trial (NETT) offers insight into this population...
  8. pmc Urokinase-type plasminogen activator increases hepatocyte growth factor activity required for skeletal muscle regeneration
    Thomas H Sisson
    Department of Medicine, University of Michigan, Ann Arbor, USA
    Blood 114:5052-61. 2009
    ..Together, our findings demonstrate that uPA promotes muscle regeneration through HGF activation and subsequent myoblast proliferation...
  9. pmc Integrating health status and survival data: the palliative effect of lung volume reduction surgery
    Roberto Benzo
    Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota 55902, USA
    Am J Respir Crit Care Med 180:239-46. 2009
    ..This practice tends to inflate the apparent benefits of interventions with a high risk of mortality. Assessing a composite QoL-death outcome is a potential solution to this problem...
  10. pmc Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1
    Sheila Chuang-Tsai
    Department of Internal Medicine, Pulmonary and Critical Care Medicine Division, University of Michigan Health Sciences Center, Ann Arbor, Michigan 48109, USA
    Am J Pathol 163:445-52. 2003
    ..In conclusion, PAI-1 deficiency appears to affect fibrotic tissue formation in part by altering the provisional matrix that forms soon after tissue injury...
  11. pmc Sex differences in severe pulmonary emphysema
    Fernando J Martinez
    University of Michigan, Division of Pulmonary and Critical Care Medicine, Ann Arbor, Michigan 48109 0360, USA
    Am J Respir Crit Care Med 176:243-52. 2007
    ..Limited data on sex differences in advanced COPD are available...
  12. pmc Anxiety is associated with diminished exercise performance and quality of life in severe emphysema: a cross-sectional study
    Nicholas D Giardino
    Mental Health Service, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA
    Respir Res 11:29. 2010
    ..The purpose of this study is to determine whether there is an association between anxiety and functional measures, quality of life and dyspnea...
  13. pmc Predictors of mortality in patients with emphysema and severe airflow obstruction
    Fernando J Martinez
    Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, MI 48109 0360, and Section of Thoracic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Am J Respir Crit Care Med 173:1326-34. 2006
    ..Limited data exist describing risk factors for mortality in patients having predominantly emphysema...
  14. pmc Variability of spirometry in chronic obstructive pulmonary disease: results from two clinical trials
    Laura B Herpel
    The Johns Hopkins University School of Medicine, Division of Pulmonary and Critical Care Medicine, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA
    Am J Respir Crit Care Med 173:1106-13. 2006
    ..This may be applied to determine criteria that can be used to assess a clinically meaningful change in spirometry...
  15. pmc Longitudinal change in the BODE index predicts mortality in severe emphysema
    Fernando J Martinez
    Division of Pulmonary and Critical Care Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0360, USA
    Am J Respir Crit Care Med 178:491-9. 2008
    ..We hypothesized that decrease in a modified BODE (mBODE) would predict survival in National Emphysema Treatment Trial (NETT) patients...
  16. pmc Plasminogen activation induced pericellular fibronectin proteolysis promotes fibroblast apoptosis
    Jeffrey C Horowitz
    University of Michigan Medical Center, 6301 MSRB III, 1150 W Medical Center Dr, Ann Arbor, MI 48109 5642, USA
    Am J Respir Cell Mol Biol 38:78-87. 2008
    ..These findings support a novel role for the plasminogen activation system in the regulation of fibroblast apoptosis and a potential role of TGF-beta1/PAI-1 in promoting (myo)fibroblast survival in chronic fibrotic disorders...
  17. ncbi request reprint Localization of plasminogen activator activity within normal and injured lungs by in situ zymography
    Teruaki Nishiuma
    Pulmonary and Critical Care Medicine Division, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
    Am J Respir Cell Mol Biol 31:552-8. 2004
    ..We conclude that analysis of BALF does not adequately reflect the fibrinolytic activity that persists within microenvironments of the lung during inflammation...
  18. pmc Physical activity, health status and risk of hospitalization in patients with severe chronic obstructive pulmonary disease
    Roberto P Benzo
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Respiration 80:10-8. 2010
    ..Self-reported daily physical activity and health status have been reported as predictors of a hospitalization in COPD but are not routinely assessed...
  19. pmc Perfusion scintigraphy and patient selection for lung volume reduction surgery
    Divay Chandra
    Division of Pulmonary and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Am J Respir Crit Care Med 182:937-46. 2010
    ..It is unclear if lung perfusion can predict response to lung volume reduction surgery (LVRS)...
  20. pmc A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia
    Kevin K Kim
    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI 48109 0642, USA
    Mol Med 9:52-6. 2003
    ..Patients with usual interstitial pneumonia did not show the same relationship with PAl-1 genotype...
  21. pmc The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism
    Noboru Hattori
    Tazuke Kofukai Medical Research Institute, Department V of Oncology, Kitano Hospital, Osaka, Japan
    Am J Pathol 164:1091-8. 2004
    ....
  22. ncbi request reprint Mice deficient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration
    Timothy J Koh
    Department of Movement Sciences M C 194, University of Illinois at Chicago, 901 W Roosevelt Rd, Chicago, Illinois 60608, USA
    Am J Physiol Cell Physiol 289:C217-23. 2005
    ..Taken together, these results indicate that PAI-1 deficiency promotes muscle regeneration, and this protease inhibitor represents a therapeutic target for enhancing muscle regeneration...
  23. ncbi request reprint Cell specific control of coagulation and fibrinolysis within the lung
    Thomas H Sisson
    Thromb Haemost 92:435-7. 2004

Research Grants5

  1. PLASMIN, FIBRIN, AND METALLOPROTEINASES IN LUNG FIBROSIS
    Thomas Sisson; Fiscal Year: 2004
    ..The opportunities provided by the training program will provide the foundation for career advancement and hopefully lead to new therapies for fibrotic lung diseases. ..
  2. The Anti-protease and Vitronectin-binding Functions of PAI-1 in Lung Fibrosis
    Thomas Sisson; Fiscal Year: 2007
    ..Ultimately, it is our goal with these studies to help guide the development of new inhibitory agents and/or novel therapeutic strategies for this difficult to treat disease. ..
  3. The Anti-protease and Vitronectin-binding Functions of PAI-1 in Lung Fibrosis
    Thomas H Sisson; Fiscal Year: 2010
    ..Ultimately, it is our goal with these studies to help guide the development of new inhibitory agents and/or novel therapeutic strategies for this difficult to treat disease. ..